{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:13:02Z","timestamp":1783912382400,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.neurol.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T19:33:32Z","timestamp":1477596812000},"page":"703-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm"],"prefix":"10.1016","volume":"172","author":[{"given":"E.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nighoghossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Praire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Desestret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Derex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vighetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2016.09.010_bib0205","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bcmd.2012.06.004","article-title":"Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications","volume":"49","author":"Malak","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.neurol.2016.09.010_bib0210","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1468-1331.2010.03183.x","article-title":"Ischaemic stroke and essential thrombocythemia: a series of 14 cases","volume":"18","author":"Richard","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0220","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2016.09.010_bib0225","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.neurol.2016.09.010_bib0230","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1212\/WNL.0000000000000430","article-title":"Pearls & Oy-sters: polycythemia vera presenting with ischemic strokes in multiple arterial territories","volume":"82","author":"Billakota","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.09.010_bib0235","first-page":"CD006503","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia","author":"Squizzato","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2016.09.010_bib0240","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0035-3787(04)71140-6","article-title":"[Cerebral infarction of arterial origin and haematological causation: the Lausanne experience and a review of the literature]","volume":"160","author":"Gonthier","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2016.09.010_bib0245","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2016.09.010_bib0250","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2013-10-531665","article-title":"Causal role for JAK2 V617F in thrombosis","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2016.09.010_bib0255","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neurol.2016.09.010_bib0260","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2016.09.010_bib0265","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.neurol.2016.09.010_bib0270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.neurol.2016.09.010_bib0275","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2008.150318","article-title":"Ischaemic stroke subtypes and associated risk factors: a French population based study","volume":"79","author":"Bejot","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2016.09.010_bib0280","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000354634","article-title":"Population-based validation of the iScore for predicting mortality and early functional outcome in ischemic stroke patients","volume":"41","author":"Bejot","year":"2013","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neurol.2016.09.010_bib0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000267281","article-title":"JAK2 V617F mutation associated with cerebral venous thrombosis: a report of five cases","volume":"29","author":"Godeneche","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.neurol.2016.09.010_bib0290","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2012.09.012","article-title":"Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders","volume":"323","author":"De","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2016.09.010_bib0295","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.neurol.2016.09.010_bib0300","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0035-3787(07)90467-1","article-title":"[Cerebral venous thrombosis secondary to essential thrombocythemia]","volume":"163","author":"Messouak","year":"2007","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2016.09.010_bib0305","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2016.09.010_bib0310","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jns.2013.10.016","article-title":"Stroke in essential thrombocythemia","volume":"336","author":"Posfai","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2016.09.010_bib0315","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.neurol.2016.09.010_bib0320","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3324\/haematol.2011.050005","article-title":"Neurological disorders in essential thrombocythemia","volume":"96","author":"Billot","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.neurol.2016.09.010_bib0325","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.07.003","article-title":"Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy","volume":"23","author":"Naganuma","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.neurol.2016.09.010_bib0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.01.005","article-title":"Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia","volume":"21","author":"Kim","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.neurol.2016.09.010_bib0335","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000360388","article-title":"Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera","volume":"133","author":"Michiels","year":"2014","journal-title":"Acta Haematol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0340","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.12.013","article-title":"An unusual cause of cerebellar hemorrhage in a young patient: essential thrombocythemia","volume":"23","author":"Adam","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.neurol.2016.09.010_bib0345","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00062752-199809000-00004","article-title":"Bleeding and thrombosis in myeloproliferative disorders","volume":"5","author":"Landolfi","year":"1998","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0350","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2016.09.010_bib0355","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","author":"Gruppo Italiano Studio Policitemia","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neurol.2016.09.010_bib0360","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1468-1331.2001.00217.x","article-title":"Diffusion-weighted magnetic resonance imaging in two patients with polycythemia rubra vera and early ischemic stroke","volume":"8","author":"Koennecke","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0365","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1752-1947-7-131","article-title":"Acute embolic cerebral ischemia as an initial presentation of polycythemia vera: a case report","volume":"7","author":"Zoraster","year":"2013","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.neurol.2016.09.010_bib0370","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.4081\/hr.2012.e12","article-title":"Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm","volume":"4","author":"Kalala","year":"2012","journal-title":"Hematol Rep"},{"key":"10.1016\/j.neurol.2016.09.010_bib0375","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs","volume":"89","author":"Crisa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0380","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/STROKEAHA.113.003720","article-title":"Evaluation of cryptogenic stroke with advanced diagnostic techniques","volume":"45","author":"Bang","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.neurol.2016.09.010_bib0385","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2011.02.004","article-title":"Hematological disorders related cerebral infarctions are mostly multifocal","volume":"304","author":"Fagniez","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2016.09.010_bib0390","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1538-7836.2007.02616.x","article-title":"JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder","volume":"5","author":"Pardanani","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.neurol.2016.09.010_bib0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1309\/AJCP7VO4HAIZYATP","article-title":"JAK2 mutations across a spectrum of venous thrombosis cases","volume":"134","author":"Shetty","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.neurol.2016.09.010_bib0400","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1751-553X.2010.01275.x","article-title":"JAK2V617F mutation in patients with thrombosis: to screen or not to screen?","volume":"33","author":"Xavier","year":"2011","journal-title":"Int J Lab Hematol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:12:13Z","timestamp":1657559533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378716300339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0035378716300339"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2016.09.010","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}